Treatment of prolonged convulsive seizures in children; a single centre, retrospective, observational study

Danique R M Vlaskamp1, Oebele F Brouwer1, Petra M C Callenbach1

  • 1Department of Neurology, University Medical Centre of Groningen, Groningen, The Netherlands.

Insights

Rectal diazepam remains a common first-line treatment for prolonged convulsive seizures (PCS) in children, despite evidence favoring buccal midazolam. Clonazepam is also frequently used off-guideline for PCS management.

Area of Science:

  • Pediatric Neurology
  • Emergency Medicine
  • Clinical Pharmacology

Background:

  • Prolonged convulsive seizures (PCS) require prompt and effective treatment in children.
  • Established treatment guidelines exist for convulsive status epilepticus (CSE), but adherence and real-world practice may vary.
  • Understanding current treatment patterns is crucial for optimizing pediatric seizure management.

Purpose of the Study:

  • To evaluate the treatment practices for pediatric prolonged convulsive seizures (PCS) at the University Medical Centre Groningen (UMCG).
  • To compare current treatment strategies with the 2005 Dutch guideline for CSE.
  • To identify trends and deviations in the management of pediatric PCS.

Main Methods:

  • Retrospective analysis of a UMCG database of children (<18 years) with epilepsy and their first seizure between 2000-2010.
  • Inclusion criteria: PCS lasting ≥10 minutes, occurring between January 2000 and October 2012 in children >1 month.
  • Analysis of treatment order, timing, location, and comparison with the 2005 Dutch guideline.

Main Results:

  • 269 PCS episodes in 102 children were analyzed; most started outside the hospital and lasted 10-30 minutes.
  • Rectal diazepam was the most frequent first-line treatment (59.6% for first PCS, 43.9% for subsequent PCS).
  • A trend towards buccal midazolam emerged since 2006; clonazepam was a common second-line choice despite not being guideline-recommended.

Conclusions:

  • Rectal diazepam continues to be the primary choice for PCS management in this cohort, despite the superior efficacy of buccal midazolam.
  • Clonazepam is frequently utilized as a second-line agent, deviating from formal Dutch treatment recommendations.
  • Clinical practice for pediatric PCS may not fully align with established guidelines, highlighting areas for potential educational intervention and guideline reinforcement.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
36
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K